Considering that IDH1 mutations can impair the repair of double-stranded DNA breaks [142, 143], several clinical trials of poly(ADP-ribose) polymerase inhibitors are enrolling patients with IDH1-mutated CCA, such as olaparib (NCT03212274), olaparib in combination with the ATR inhibitor ceralasertib (NCT03878095), and olaparib plus durvalumab (NCT03991832). Here, IDH1 is linked to cholangiocarcinoma.